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Death within a month after the administration of cancer
chemotherapy is a rare event occurring after 0.5% to 5% of
conventional chemotherapy courses (Sculier et al, 1984; Antman
et al, 1993; Fisher et al, 1993; Hussain et al, 1991; Radford et al,
1993; Lilienbaum et al, 1998). These early deaths may result either
from the toxicity of chemotherapy, disease progression or both.
Sepsis-related death in neutropenic patients is the most frequent
cause of mortality due to the toxicity of chemotherapy, although
other causes such as renal, cardiac or neurological lethal toxicities
are not infrequent (Sculier et al, 1984; Hussain et al, 1993; Radford
et al, 1996; Lilienbaum et al, 1998). Parameters influencing the risk
of early death after chemotherapy in cancer patients are not well
known, although it is generally reported that a poor performance
status predicts a poor outcome after chemotherapy in most cancer
types (Morittu et al, 1989; Komaki et al, 1993; Shipp et al, 1993;
Gomez et al, 1998). This work was initiated to identify risk factors
for early death in patients receiving chemotherapy. Early death was
defined here as a death within 31 days after the administration of
chemotherapy, an event for which a contribution of chemotherapy is
generally considered in clinical studies (Kramer et al, 1979; Begaud
et al, 1985). A risk model based on patient’s characteristics was
delineated and then validated in 3 distinct series of patients. 
PATIENTS AND METHODS 
The method used in this study was (1) to identify independent risk
factors for early death in a large retrospective series of patients
with various tumour types, (2) to delineate a risk index for early
death and (3) to validate this index in 3 different series of patients. 
Criteria for patient selection 
4 distinct cohorts of patients are considered in this analysis. In all
4 series, the selection criteria for patients were identical and as
follows: patients had to be older than 17 years and to be treated
with a chemotherapy regimen. Patients previously treated outside
the centre were eligible. Patients receiving chemotherapy regi-
mens administered daily, or treated concomitantly with interferon
or interleukin-2 were excluded as well as patients receiving high-
dose chemotherapy regimens requiring bone marrow or peripheral
blood stem cell reinjection. Since baseline blood cell counts were
tested as prognostic factors in view of their prognostic value for
haematological toxicity, leukaemia and follicular lymphomas with
blood involvement were excluded from this study: these repre-
sented 7 patients in the CLB-1996 series, of whom none had
lymphocyte count under 700 µ l–1 and none died within 31 days
after the first chemotherapy administration. Each patient was
included only once in the 4 series. 
The retrospective group of 1996 (CLB-1996) comprised all
patients treated with cytotoxic chemotherapy in the Department of
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Medicine of the Centre Léon Bérard in 1996 who matched the
selection criteria. 3223 chemotherapy courses were given to 1116
patients in 1996. Every patient was analysed only for his/her first
course of chemotherapy given in 1996 in the Centre Léon Bérard.
Information about histology, stage at diagnosis, line of
chemotherapy, number of previous courses, primary tumour site,
chemotherapy regimen, gender, age, performance status (PS),
blood cell count on day 1 (d1) just before the administration of
chemotherapy were collected. Patients with a missing blood cell
count at day 1 (n = 65) were excluded. Therefore 1051 of the 1116
patients (94%) were analysed. Co-morbidities susceptible to
increase the risk of death were reported in 178 of these 1051
patients (17%): 99 (9%) had cardiac diseases, 23 (2%) hepatic
diseases, 47 (5%) lung diseases, 9 (1%) neuropsychiatric disor-
ders. The risk model was established in this retrospective series. 
The first validation group (CLB-1997) is the retrospective series
of 797 patients treated in the Centre Léon Bérard during 1997 and
who had not received chemotherapy in the Department of
Medicine of the Centre Léon Bérard in 1996. All patients were
analysed only for their first course of chemotherapy given in 1997
in the Centre Léon Bérard. 
The second validation group (NHL-CLB) is a cohort of 149
non-pretreated patients with intermediate- or high-grade non-
Hodgkin’s lymphoma who received a first course of conventional
chemotherapy regimen in the Centre Léon Berard between 1987
and 1995 while included in prospective multicentric phase III
trials of the multicentric groupe d’étude des lymphomes de
l’adulte (GELA) group. There were no missing data in this series
and all patients were evaluated. 
The third validation group (MBC) is a multicentric prospective
phase III series including 309 female patients with hormono-resis-
tant metastatic breast cancer treated with the CEF regimen
(cyclophosphamide, epirubicin, fluorouracile) in first line in both
the Centre Léon Bérard (n = 197, 64%) and in general hospitals of
the French Rhône-Alpes region (n = 112, 36%) between 1985 and
1990 (Chauvin et al, 1990). Only 286 of the 309 (93%) patients
included in this series were analysed because of missing day-1
blood cell count (n = 5) or missing performance status (n = 18). 
The main characteristics of the 4 series of patients are presented
in the Table 1. 
Definition of early death 
The major endpoint of this study was the death of the patient
within 31 days following day 1 of chemotherapy administration,
referred to as early death, resulting either from toxicity, disease
progression or both. In most clinical trials in oncology, and
according to Good Clinical Practice, death within 31 days is an
event for which a possible role of chemotherapy is generally
considered since chronological delay is suggestive (Kramer et al,
1979; Begaud et al, 1985). 
Chemotherapy regimens 
Chemotherapy regimens were separated into 2 subgroups
according to the doses of drugs administered, as reported in
previous ELYPSE studies (Blay et al, 1996, 1997, 1998; Ray-
Coquard et al, 1999). The ‘high-risk regimen’ were defined
according to the initial recommendations of the French Ministry of
Health for the use of G-CSF or GM-CSF: in these recommenda-
tions, the use of G-CSF or GM-CSF was restricted to those patients
receiving regimens including at least these doses of chemotherapy
(for anthracyclines, alkylating agents and VP16). For CDDP and
cytosine arabinoside, the threshold of doses chosen were those used
internally within the CLB to select patients for primary prophylaxis
with nG-CSF or GM-CSF. ‘High risk’ chemotherapy regimens, as
defined in this study are regimens containing doxorubicin or
epirubicin ≥ 90 mg m–2, or cisplatin ≥ 100 mg m–2, or ifosfamide
≥ 9g  m –2, or cyclophosphamide ≥ 1g  m –2, or etoposide
≥ 500 mg m–2, or cytarabine ≥ 1g  m –2 per course. The other
subgroup includes all other chemotherapy regimens. 
Statistical analysis 
Statistical analysis was performed using the procedures of the
SPSS® 8.0 program (Chicago: SPSS, Inc, 1998) following a 3-step
design. 
Step 1: Risk factors for early death were tested in univariate
and multivariate analysis in the 1051 patients of the CLB-1996
series. The correlation between a clinical or a biological parameter
and the incidence of early death was performed using the Pearson
χ 2 test or Fisher’s exact test. A logistic regression including the
parameters studied in the univariate analysis was performed using
the logistic program of SPSS®: a forward regression procedure
was used with a P value < 0.05 for entry. Risk factors (e.g. PS > 1)
and end-point (i.e. early death) were introduced in the model as
dummy variables. For most biological values, normal levels were
considered as the threshold level, with the exception of
lymphopenia ≤ 700 µ l–1, which was selected because of its predic-
tive value for haematological toxicity of chemotherapy in previous
studies of the Elypse group (Blay et al, 1996, 1997, 1998; Ray-
Coquard et al, 1999). For other parameters (age, stage, number of
previous courses of chemotherapy, number of previous lines of
chemotherapy), the most relevant threshold was used in univariate
analysis. For instance, we tested different cut-off values for age
every 10 years from 30 to 80: 60 was found to be the most relevant
threshold in univariate analysis and was kept for this reason. 
Step 2: Using the parameters value of the logistic regression, 3
subsets of patients were identified according to the cumulative risk
of early death, i.e. patients with none, one and both risk factors. 
Step 3: The discriminant power of this classification was
confirmed in the 3 validation series by comparing the observed
numbers of early deaths to the calculated number of deaths
according to the model using a χ 2 test. Finally, the negative predic-
tive value (NPV) of the model was calculated in CLB-1997, CLB-
NHL and MBC series as the posterior probability of no early death
for patients without risk factors (1-NPV is the probability of early
death for patients without risk factors). The relative risk of the
high-risk group is estimated as the positive predictive value
divided by 1-NPV. 
In addition, the incidence of death at 3 months was investigated
in the 3 risk groups of the 4 series. 
RESULTS 
Risk factors for early death after chemotherapy 
43 of the 1051 patients of the CLB-1996 group (4.1%) died within
the 31 days following the administration of their first course of
cytotoxic chemotherapy in 1996 (Table 2). In 23 cases (53%)
death was considered to result only from the toxicity of the treat-
ment (18 septic shock, 2 cardiac failures, 2 pulmonary embolism
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in patients bedridden following chemotherapy, 1 suicide in the
context of severe mucositis, marrow aplasia and depression
following administration of a 5FU-CDDP-corticosteroids
regimen), while in 20 cases (47%) death was considered to be the
consequence of progressive disease with a possible contribution of
the toxicity of chemotherapy. In univariate analysis, age over 60
years, the type of chemotherapy, performance status (PS) > 1,
platelet count < 150 000 µ l–1 and lymphocyte count ≤ 700 µ l–1
immediately prior to the initiation of chemotherapy (d1) were
found to be significantly correlated (P < 0.05) to the risk of early
death (Table 3). In contrast, stage at diagnosis, gender, d1 poly-
morphonuclear leukocyte (PMN) count < 1500 µ l–1, d1 haemo-
globin count < 12 g dl–1, the line of chemotherapy regimen (first
vs. other), chemotherapy regimen containing cisplatin, single
agent vs. combination chemotherapy, and the presence of co-
morbidities were not significantly correlated with the incidence of
Table 1 Characteristics of the patients 
CLB-1996 CLB-1997 CLB LNH MBC TOTAL 
(n = 1051) (n = 797) (n = 149) (n = 286) (n = 2283) 
No of pts (%) No of pts (%) No of pts (%) No of pts (%) No of pts (%) 
Median age (range) 55 (18–86) 55 (18–88) 70 (20–93) 56 (27–70) 57 (18–93) 
Age, years 
< 60 655 62 489 61 37 25 193 67 1374 60 
≥ 60 396 38 308 39 112 75 93 33 909 40 
Sex 
Female 567 54 442 55 68 46 286 100 1363 60 
Male 484 46 355 45 81 54 0 0 920 40 
Diagnosis 
Carcinoma 
Breast 247 24 223 28 0 0 286 100 756 33 
Colon-rectum 96 9 57 7 0 0 0 0 153 8 
Ovary 90 9 41 5 0 0 0 0 131 7 
Head and neck 103 10 54 7 0 0 0 0 157 8 
Other gastrointestinal 92 9 39 5 0 0 0 0 131 7 
Lung cancer 61 6 67 8 0 0 0 0 128 6 
Other carcinoma (genitourinary, 
gynaecologic, thyroid, unknown) 97 9 103 13 0 0 0 0 200 9 
Bane and soft tissue sarcoma 68 6 53 7 0 0 0 0 121 6 
Lymphoma 93 9 61 8 149 100 0 0 303 13 
Othera 104 10 99 12 0 0 0 0 203 9 
High-risk chemotherapyb 
Yes 103 10 199 25 74 50 0 0 376 17 
No 948 90 598 75 75 50 286 100 1907 83 
Chemotherapy regimens 
ACVBP/ECVBP 14 1 18 3 74 50 0 0 106 5 
Doxorubicin alone 27 3 26 3 0 0 0 0 53 2 
Cisplatin-5FU 85 8 33 4 0 0 0 0 118 2 
Cisplatin-vinorelbine/cisplatin-VP16 55 5 40 5 0 0 0 0 95 4 
DHAP 24 2 16 2 0 0 0 0 40 1 
CAF/CEF/AC 115 11 103 13 0 0 286 100 504 22 
5FU-leucoverin/LV5FU2 71 7 37 5 0 0 0 0 108 5 
MBACOD 0 0 0 0 15 10 0 0 15 1 
MAID 11 1 9 1 0 0 0 0 20 1 
TAXANES 124 12 89 11 0 0 0 0 213 10 
CHOP/CEOP 25 2 27 3 53 36 0 0 105 5 
BEP/EP 30 3 31 4 0 0 0 0 61 3 
Vinorelbine alone 74 7 57 7 0 0 0 0 131 5 
5FU-leucoverin-oxaliplatin 34 3 14 2 0 0 0 0 48 2 
Other 362 34 297 37 7 5 0 0 666 29 
No of chemotherapy courses 
1 822 78 721 90 149 100 286 100 1978 87 
≥ 2 229 22 76 10 0 0 0 0 305 13 
No of previous lines of chemotherapy 
0 618 59 497 62 149 100 127 43 1391 61 
≥ 1 433 41 300 38 0 0 159 54 892 39 
Stage at diagnostic 
1–2 658 63 510c 64 71 48 143d 55 1382 61 
3–4 393 37 283c 36 78 52 68d 26 822 36 
Performance status 
0–1 881 84 669 84 103 69 172 60 1825 80 
> 1 170 16 128 16 46 31 114 40 458 20 
aMelanoma, germ cell tumours, myeloma, mesothelioma, glioma, bsee Material and methods, cmissing data = 4, dmissing data: n = 5.  
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early death (Table 3). Interestingly, although the number of
previous courses of chemotherapy was significantly correlated to
lymphopenia counts (median lymphocyte count 1330 vs 1190 µ l–1
in patients who previously received 0–1 vs >1 course, P = 0.007),
this parameter was not significantly correlated to the risk of ED in
this series. A logistic regression was performed to identify inde-
pendent risk factors for early death including the parameters tested
in the univariate analysis. The parameters identified as indepen-
dent risk factors for early death were PS > 1 (OR: 3.9 (95% CI
2–7.5)), and d1-lymphocyte count ≤ 700 µ l–1 (OR: 3.1 (95% CI
1.8–5.8)). Of note, the same 2 independent parameters influenced
the risk of ED due to toxicity only in this series (23 patients). 
A risk model for early death after chemotherapy 
Since the relative risk associated with the 2 independent factors
were similar, 3 subgroups of patients with a different risk of
early death were considered: patients with both risk factors 
(high-risk group), patients with only 1 of the 2 risk factors (inter-
mediate risk group), patients with none of these 2 risk factors
(low-risk group) (Table 4). The calculated probability to die within
the 31 days following chemotherapy was 20% (95% CI, 10–31%)
for patients of the high-risk group, 6% (95% CI, 4–9%) for
patients in the intermediate risk group, 1.7% (95% CI, 0.9–3%) for
patients in the low-risk group. The observed incidences of early
death in the 3 groups were found to be significantly different in the
CLB-1996 cohort (P < 10–5). The relative risk of early death (see
Statistical methods) in the high-risk group is 7.32 compared to the
intermediate- plus low-risk groups. 
Validation of the model (Table 4) 
The observed incidence of early death in the 4 series were signifi-
cantly different (43 of 1051 (4.1%), vs. 37 of 797 (4.6%), vs. 15 of
149 (10%), vs. 11 of 286 (3.8%) (χ 2 = 11.1, P = 0.01) in the CLB-
1996, in the CLB-1997, in the CLB-NHL and in the MBC series,
respectively. In the CLB-1997 series, the observed incidence of
early death was 19% (8 of 42), 9% (20 of 218), 1.7% (9 of 537)
respectively in the high-, intermediate and low-risk groups 
(P < 10–5) (Table 4). In the CLB-NHL series, the observed inci-
dence of early death was 40% (4 of 10), 9% (5 of 53), 7% (6 of 86)
respectively in these 3 groups (P < 10–5) (Table 4). In the MBC
series, 4 of 16 (25%) patients with both risk factors experienced
early death as compared to 5 of 126 (4%) for the intermediate-risk
group and 2 of 144 (2%) for the low-risk group (P < 10–3). The
negative predictive value of the model is respectively 0.96, 0.92
and 0.97 for the 3 validation series as compared to 0.97 in the CLB-
1996 series. The relative risks of early death of the high-risk group
vs. intermediate- and low-risk group in the 3 validation series are,
respectively, 4.96, 5.05 and 9.64. The calculated number of deaths
according to the model was not significantly different from the
observed number of death in the 3 validation series (not shown). 
Survival beyond 1 month in the 3 groups 
The observed incidence of death at 3 months for patients of the
high- intermediate and low-risk groups were 45% (29 of 65), 18%
(49 of 274) and 4.8% (34 of 712) in the CLB-1996 cohort, 43%
(18 of 42), 22% (49 of 218) and 5% (89 of 537) in the CLB-1997
cohort, 50% (5 of 10), 26% (14 of 53) and 13% (11 of 86) in CLB-
NHL cohort, 38% (6 of 16), 16% (20 of 126) and 3% (4 of 144) in
the MBC series. In these 4 series, 44% (58/133) of the patients of
the high-risk group therefore died within 3 months. 
Finally, it was asked whether the present model could identify
patients at high risk for early death at any given point during their
career receiving chemotherapy. Among the database of 3223
chemotherapy courses given in the Department of Medicine of the
CLB in 1996, 2481 courses were given in patients in whom both
day-1 PS and day-1 lymphocyte counts were available. Overall, 78
patients experienced early death following one of these 2478 assess-
able courses in 1996: 25 ED occurred after 154 (16%) courses given
to patients in the high-risk group, 35 after 788 courses (4%) given to
patients in the intermediate-risk group, and 18 after 1539 courses
(1.2%) to patients in the low-risk group (χ 2 = 110, P < 10–5). 
DISCUSSION 
Although rare, early death after the administration of
chemotherapy is a major concern for the physician prescribing
chemotherapy. The identification of patients at high risk for this
event would be useful in clinical practice in order to propose an
intensive surveillance between courses, or alternatively to make
the decision to postpone the administration of chemotherapy, in
particular in palliative situations. There is however, no published
model enabling the identification of patients at high risk for early
death following chemotherapy. The objective of this study was to
analyse risk factors for early mortality after the administration of
conventional chemotherapy, and to delineate a simple risk index
for early death after chemotherapy which could be used in all
tumour types in clinical practice. Only simple and readily avail-
able clinical and biological parameters in routine clinical practice
were considered in this study. 
Table 2 Description of regimens given in patients experiencing early death
Regimen Total Death Day of death 
nn (%) median (range) 
Vinorelbine weekly 74 7 (9%) 18 (9–27) 
Cisplatin-5 fluorouracil 85 5 (6%) 18 (5–31) 
Vinorelbine-cisplatin 34 4 (12%) 16 (7–28) 
Cisplatin-etoposide 21 3 (14%) 14 (10–23) 
CAF/CEF 115 3 (3%) 9 (3–15) 
Other platinum-containing regimens 52 6 (12%) 9 (2–24) 
CHOP-like regimens 29 3 (10%) 16 (1–17) 
Mitoxantrone-containing regimens 13 3 (23%) 11 (5–17) 
Ifosfamide-containing regimens 30 3 (10%) 20 (18–23) 
5-FU-containing regimens 80 2 (2%) 14 (10–18) 
Other 37 4 (11%) 7 (4–23) 
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The first difficulty in addressing this issue is the definition of
early death and the contribution of chemotherapy to this outcome.
In most toxicity scale grading published to date, and in particular
for the analysis of clinical trials, it is considered that death within
a month following the administration of chemotherapy should be
attributed, unless otherwise proven, to the toxicity of chemo-
therapy (Kramer et al, 1979; Begaud et al, 1985). However, the
causality relationship between administration of chemotherapy
and the death of the patient is sometimes difficult to demonstrate.
For practical purpose, the major endpoint of this study was chosen
to be ‘early death’, as defined by death within 31 days following
administration of chemotherapy: in the present study, early death
could result from both the toxicity of chemotherapy and/or from
chemotherapy failure, i.e. disease progression. 
It has been reported that poor performance status, poor bone
marrow reserve, pre-existing organ dysfunction and denutrition
are risk factors for chemotherapy-related mortality (Morritu et al,
1989; Komaki et al, 1993; Kimmick et al, 1997). In the present
Table 3 Risk factors for early death after chemotherapy in the CLB 1996 series 
Number of patients (%) Early Death P
n % 
Age, years 0.04 
≤ 60 655 (62) 21 3.2 
> 60 396 (38) 22 5.6 
Stage at diagnostic 0.32 
1–2 658 (63) 25 3.8 
3–4 393 (37) 18 4.6 
Sex 0.41 
Female 567 (54) 22 3.9 
Male 484 (46) 21 4.3 
# of chemotherapy courses 0.13 
1 822 (78) 37 4.5 
≥ 2 229 (22) 6 2.6 
# of previous lines of chemotherapy 0.19 
0 618 (59) 22 3.6 
≥ 1 433 (41) 21 4.8 
High risk chemotherapya 0.01 
Yes 103 (10) 0 0 
No 948 (90) 43 4.5 
Co-morbidities 0.29 
Yes 178 (17) 9 5 
No 873 (83) 34 4 
Histological type 0.92 
Carcinoma 786 (75) 33 4.2 
Lymphoma 93 (9) 4 3.5 
Sarcoma 68 (6) 3 4.3 
Otherb 104 (10) 3 3.5 
Performance status <0.001 
0–1 881 (84) 23 2.6 
> 1 170 (16) 20 11.8 
d1 hemoglobin count 0.07 
< 12 g dl–1 510 (48) 26 5.1 
≥ 12 g dl–1 541 (52) 17 3.1 
d1 lymphocyte count <0.001 
≤ 700 µ l–1 234 (22) 22 9.4 
> 700 µ l–1 817 (78) 21 2.6 
d1 platelet count 0.01 
< 150 000 µ l–1 100 (10) 9 9 
≥ 150 000 µ l–1 951 (90) 34 3.6 
d1 PMN count 0.7 
< 1500 µ l–1 26 (3) 1 3.8 
≥ 1500 µ l–1 1025 (97) 42 4.1 
Regimen containing platinum salts 0.5 
Yes 430 (41) 18 4.2 
No 621 (59) 25 4 
Single agent chemotherapy 0.17 
Yes 288 (27) 15 5.2 
No 763 (73) 28 3.7 
Prophylactic G-CSF 0.6 
Yes 101 (10) 4 4 
No 950 (90) 39 4.1 
aSee Materials and Methods; bsee Table 1. 
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study, only 2 independent risk factors for early death were identi-
fied among those tested: performance status >1 and lymphopenia
≤ 700 µ l–1. Performance status has already been reported as 
an independent predictor for chemotherapy-related death in
lymphomas and lung carcinomas (Morittu et al, 1989; Komaki
et al, 1993; Shipp et al, 1993; Gomez et al, 1998) and has also been
found to be correlated to the risk of severe infection in cancer
patients (Hussain et al, 1991; Kimmick et al, 1997). 
Lymphopenia, in contrast, had not been previously reported as a
risk factor for early death after chemotherapy in HIV-negative
patients, although it is an independent prognostic factor for febrile
neutropenia, thrombocytopenia, and anaemia in studies of the
ELYPSE group (Blay et al, 1996, 1997, 1988; Ray-Coquard et al,
1999), and a prognostic factor for overall survival in a study
published in 1970 (Riesco, 1970). The threshold level of 700
lymphocytes per µ l was selected because of its predictive value for
haematological toxicities in these previous studies but its biolog-
ical significance remains unclear (Blay et al, 1996, 1997, 1988;
Ray-Coquard et al, 1999). At the present time, it is not known
whether lymphopenia is restricted or not to a specific lymphocyte
subset in these patients. The mechanism of lymphopenia in cancer
patients is unclear. Although it may reflect denutrition in some
cases (Marks, 1977; Grant et al, 1981; Hussain et al, 1991), this is
probably not the sole cause since other parameters of denutrition,
such as weight loss and hypoalbuminaemia are observed in less
than 40% of lymphopenic cancer patients (now shown). Of note,
since nutritional status was not documented for each patient in the
electronic file from which data were extracted, this specific point
was not tested as a predictive factor in these series. 
Lymphopenia may also result from cumulative myelosuppres-
sion from prior chemotherapy courses: indeed a significant corre-
lation was observed between the number of previous courses and
lymphopenia. Among possible causes, lymphopenia may result
from a destruction of lymphocytes elicited by the tumour and/or
from an impairment of the differentiation of lymphocyte progeni-
tors in vivo in cancer patients. For instance, it has been recently
reported that lymphocytes of cancer patients undergo activation-
induced death in vivo (Saito et al, 2000). The contribution of
proapoptotic ligands such as FasL or TNFα has been debated since
tumour cells frequently produce or induce the production of these
cytokines (Strand et al, 1996; Tanaka et al, 1996; Voorzanger et al,
1996; Restifo, 2000). This issue is currently under investigation
prospectively. 
Although only 2 independent risk factors for early death were
identified in this study, its purpose was to delineate a model with
predictive value in all tumour types and stages, with the assump-
tion that such a model would likely be more practical for daily
clinical use than a variety of different indexes for different cancer
types. The method used favoured, therefore, the identification of
parameters with a common prognostic value for early death in
different cancer types. It cannot be excluded that other clinical or
biological parameters may be correlated to early death in specific
tumour types, and may improve the predictive value of the model
described here for these specific tumour types. However, the
model proved to be predictive in heterogeneous cohorts of patients
with different tumour types as well as for 2 homogeneous series of
patients with metastatic breast carcinoma receiving first-line
chemotherapy and previously untreated aggressive NHL. 
Finally, it was chosen to report a model in which variables were
dichotomized instead of being used as continuous variables
because (1) when age, blood cell count etc. were tested as contin-
uous variables in the multivariate model, the final results, in
particular the nature of independent variables (performance status
and lymphopenia remaining the independent variables) and rela-
tive risk for each patient group were not significantly affected, and
(2) the calculation of the individual risk for each patient would be
less practical using continuous variables for daily clinical use. 
The capacity of the model to identify patients at high risk for
early death in most tumour types was confirmed by the analysis
of 3 distinct cohorts of patients, including 2 homogeneous
groups of patients with untreated aggressive NHL and with
metastatic breast carcinoma treated with first-line chemotherapy.
This is also supported by the analysis of the incidence of early
death in high-risk patients of the CLB-1996 and CLB-1997
series which ranged between 12.5% and 33% in the different
tumour types (breast, lung, head and neck, colorectal, genitouri-
nary, sarcomas, lymphomas...) and was 2.4- to 12-fold higher
than for the remaining patients with the same tumour (not
shown). Finally, no interaction between tumour type (carcinoma
vs. lymphomas vs. sarcomas vs. other) and performance status or
lymphopenia were detected in the logistic regression procedure,
further suggesting that this index has a similar value in the
different tumour types. 
The risk model described here identifies a small subgroup of
patients representing 6% of all patients in the 4 series (133 of 2283)
with a high risk of early death after chemotherapy, in whom, an
intensive surveillance during the interval could be proposed.
Actually, the identification of a patient in the high-risk group may be
useful in 2 completely opposite situations: first, for patients treated
with a curative intent and/or in first-line treatment, in whom a strict
Table 4 Incidence of early death in the 3 groups according to the risk model 
Observed incidence 
Validation series 
CLB-1996 CLB-1997 CLB-NHL MBC Total 
Calculated Incidence (95% Cl) n % n % n % n % n % 
2 risk factors 20% (10–31) 14/65 21.5% 8/42 19.0% 4/10 40% 4/16 25% 30/133 22.5% 
1 risk factor 6% (4–9) 14/274 5.1% 20/218 9.1% 5/53 9.4% 5/126 3.9% 44/671 6.5% 
no risk factor 1.7% (0.9–3) 15/712 2.1% 9/537 1.6% 6/86 6.9% 2/144 1.4% 32/1479 2.1% 
The differences between the observed numbers and calculated numbers (i.e. total number of patients × calculated incidences) of early death were not
significantly different in the 3 risk groups of the 4 validation series (χ 2 = 0.05, P = 0.82; and and χ 2 = 0.55, P = 0.46 for the CLB-1996 and CLB-1997 series,
respectively; χ 2 = 3.14, P = 0.08; for the CLB-NHL series, χ 2 = 0.17, P = 0.67; for the MBC series). 
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clinical surveillance between courses should be performed. Second,
for patients in whom treatment is palliative and who are receiving a
second or beyond line of chemotherapy; in these patients, the deci-
sion to give chemotherapy should probably be carefully discussed,
and if done, with similar precautions as in the first group. 
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